ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 22 of 42
JMBS 2017, 2(4): 121–126
Clinical Medicine

Influence of Levocarnitin Treatment during a Stable Ischemic Heart Disease in Patients with Non-Alcoholic Fatty Liver Disease and Obesity

Shevchenko T. I., Sorokina S. I., Kudrya I. P., Shaposhnyk O. A.

Metabolic syndrome which is accompanied by excess body weight is a predictor of ischemic myocardial defeat in ischemic heart disease (IHD) and non-alcoholic fatty liver disease (NAFLD). Among the medicines that provide the normalization of metabolic status, correcting dyslipidemia, we would like to emphasize levocarnitine, which has anabolic effect, reduces the main metabolism, and has antihypoxic, lipid metabolism stimulating pharmacological effect. The purpose of the study is to determine the effect of levocarnitine on the progression of IHD in combination with NAFLD and obesity. Materials and methods. The surveyed patients (68 patients with an average age of 70.32 ± 6.71 years, 0.90 (M ± SEM; SD)) were divided into two groups: the main group and the comparison group. The main group consisted of 35 patients who received levocarnitine at a dose of 20 mg/kg/day intravenously for 10 days during the period of stay in the hospital, and subsequently on the stage of outpatient treatment continued the therapy per os – 1g 2 twice a day at the background of the standard IHD pharmacotherapy for another 21 days. The control group consisted of 33 patients who received exclusively standard IHD therapy. In both groups, in addition to the general clinical trial, daily monitoring of the ECG was performed (before and after 1 month of treatment) using the Holter system "LABTECH Ltd", software version V4.04.RC14), determination of lipidogram indicators (total cholesterol level (TCL), Triglycerides (TG), low-density lipoprotein (LDL-C) and high density (HDL-C), an atherogenicity index (AI)). The presence of NAFLD (fatty liver infiltration) was diagnosed with ultrasound examination of the abdominal organs on the Logiq F8 («General Electric») apparatus. Results and discussions. As a result of the study, significant decrease in the number of episodes and duration of ischemia periods per day in all patients and a tendency to decrease of cardiac rhythm disturbance in the background of treatment with a significant advantage in the group receiving additionally levocarnitine was noticed. An improvement in the clinical status of patients evaluated by the number of angina attacks and the need for nitroglycerin was observed in both groups, but more pronounced in the patients of the main group. The dynamics of lipid metabolism indices changes testifies the positive effect of treatment at fat metabolism with a significant decrease in the level of TC, TG and the tendency to decrease LDL-C, AI and increasing of HDL-C, which is more significant in patients of the main group with the use of Levocarnitine therapy. Conclusions. Levocarnitine usage in the complex treatment of patients with stable coronary artery disease in combination with NAFLD and obesity significantly affects the normalization of lipid metabolism rates. Taking Levocarnitine for 1 month improves the clinical course of the disease, reducing the number of episodes and the duration of ischemic periods. The quality of life was improved in patients treated with Levocarnitine in addition to standard treatment, which was confirmed by reducing the number of angina attacks and the need for nitrates. Due to the similarity of pathogenetic processes in IHD and NAFLD, it is expedient to add Levocarnitine to the generally accepted treatment scheme for patients with these nosologies.

Keywords: stable ischemic heart disease, non-alcoholic fatty liver disease, obesity, Levocarnitine

Full text: PDF (Ukr) 204K

  1. Babak OYa, Kolesnikova EV. Nealkogolnaya zhirovaya bolezn pecheni i kardiovaskulyarnyy risk: sovremennyy vzglyad na problemu. Optimizatsiya terapii. Novini meditsini ta farmatsiyi. 2012; 8 (410). Available from: – Zagl s ekrana. – Data obrashcheniya: 12.07.2017. [Russian].
  2. Kolesnikova EV. Nealkogolnaya zhirovaya bolezn pecheni kak nezavisimyy faktor riska subklinicheskogo ateroskleroza. Zdorov’ya Ukrayini: medichniy portal. Available from: – Zagl. s ekrana. – Data obrashcheniya: 12.07.2017. [Russian].
  3. Skrypnyk IM, Dubrovynska TV. Optymizatsiya rannoi ta dovhotryvaloi statynoterapiyi u khvorykh na infarkt miokarda u poyednanni z nealkoholnym steatohepatytom (100.14/168.14): metodychni rekomendatsiyi; MOZ, Ukrainskyi tsentr nauk med informatsiyi ta patentno-litsenziynoi roboty. Kyiv, 2014. 36 s. [Ukrainian].
  4. Skrypnik IN. Otsenka terapevticheskikh podkhodov k lecheniyu nealkogolnogo steatogepatita v Ukraine i ego vzaimosvyaz s faktorami riska: rezultaty multitsentrovogo prospektivnogo issledovaniya DIREG_L_04443. Suchasna gastroenterologiya. 2013; 2: 64-71. [Russian].
  5. Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol. 2015; 62: 47–64.
  6. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64: 1388–402.
  7. Gastaldelli A, Kozakova M, Hшjlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B. Fatty Liver Is Associated with Insulin Resistance, Risk of Coronary Heart Disease, and Early Atherosclerosis in a Large European Population. Hepatology. 2009; 49: 1537–44.
  8. Lango R, Smolenski RT, Narkiewicz M, Suchorzewska J, Lysiak-Szydlowska W. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovasc Res. 2001; 51 (1): 21-9.
  9. Lim S, Meigs JB. Links between ectopic fat and vascular disease in humans. Arterioscler Thromb Vasc Biol. 2014; 34: 1820–6.
  10. Loria P, Lonardo A, Bellentani S, Fontana C, Carulli L, Verrone AM, Borsatti A, Bertolotti M, et al. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutrition, Metabolism and Cardiovascular Diseases. 2007; 17 (9): 684–98.
  11. Scorletti E, Calder PC, Byrne CD. Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine. 2011; 40: 332–43.
  12. Stefan N, Kantartzis K, Häring HU. Causes and Metabolic Consequences of Fatty Liver. Endocr Rev. 2008; 29 (7): 939–60.
  13. Tacer FК, Rozman D. Nonalcoholic Fatty Liver Disease: Focus on Lipoprotein and Lipid Deregulation. Journal of Lipids. 2011; 2011 (5): 1-14.
  14. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007; 191: 235–40.